PubHawk
Am J Cardiol July 2024 PMID 38679221

Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Areesha Moiz, Jeremy Y Levett, Kristian B Filion, Katya Peri, Pauline Reynier, Mark J Eisenberg

Download social card

Mentions

23
Peak: 4 in Jun 2024
across 4 sources since Apr 2024

Extended reach

43,885
potential audience

Total likes

42

Video views

717

Mentions per month

Apr 2024 – Dec 2025

Where it's discussed

  • X / Twitter12 posts
  • Facebook6 posts
  • News3 articles
  • YouTube2 videos

AI synopsis

What people are saying

Discussions consistently praise the publication, with statements like 'it works' and references to evidence supporting semaglutide's efficacy, highlighting strong agreement and interest. The tone is both supportive and analytical, emphasizing the medication's benefits and safety, reflecting deep engagement and perceived high impact on health treatments.

AgreementStrong agreement

Most reflections explicitly support the publication, emphasizing its evidence for weight loss benefits and long-term safety.

InterestHigh interest

Discussions demonstrate high curiosity, with several posts highlighting the proven effectiveness of semaglutide.

EngagementHigh engagement

Posts delve into detailed implications, quoting specific outcomes like weight loss figures and referencing related research, indicating deep involvement.

ImpactHigh impact

The overall tone suggests that many see the research as a meaningful breakthrough that could influence weight management practices broadly.

Abstract in brief

  • Semaglutide shows significant long-term weight loss benefits for individuals with overweight/obesity who do not have diabetes, according to a review of randomized controlled trials.
  • Compared to a placebo group, participants using semaglutide experienced an average weight loss of 12.3 kg and about a third achieved over 20% weight loss.
  • Although there were more gastrointestinal side effects in the semaglutide group, most were mild and temporary, making semaglutide a viable option for weight management.
Read the full abstract

Top posts

Most liked on X and Bluesky
Javier Torres
@JTLLERGO · X

⚠️ Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A SR and Meta-Analysis of RCT‼️

Jun 12, 2024 · 16 likes · 1 share · 5,193 followers View post →
IntegralAnswers
@IntegralAnswers · X

11B/ Ref: https://t.co/18yBulVJBE

Sep 1, 2025 · 5 likes · 1 share · 8,603 followers View post →
Eric Weinhandl
@eric_weinhandl · X

(1) It works. Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials - American Journal of Cardiology https://t.co/n4SrzRK70E

Apr 29, 2024 · 4 likes · 1 share · 2,801 followers View post →
Eric Cadesky MD
@drcadesky · X

If you need more proof that semaglutide (Ozempic, Wegovy) often leads to significant weight loss, here it is 10.1016/j.amjcard.2024.04.041 https://t.co/WYz2AdYTlL

Jun 1, 2024 · 3 likes · 1 share · 4,511 followers View post →
pinacol
@pinacol · X

【システマティックレビュー・メタアナリシス】糖尿病患者体重減少のための週1回セマグルチドの長期間の有効性と安全性（セマグルチドはプラセボと比較して長期間の相対的および絶対的体重減少と関連した。消化管有害事象のリスクはセマグルチドで高かった。） #ペ読 https://t.co/sDYotc1IF0

May 5, 2024 · 3 likes · 1 share · 1,683 followers View post →
PulsePilot
@Pulse1Pilot · X

RT @drcadesky: If you need more proof that semaglutide (Ozempic, Wegovy) often leads to significant weight loss, here it is 10.1016/j.amjc…

Jun 1, 2024 · 1 share · 5,250 followers View post →

All mentions

Millard Fillmore White House Library
@FillmoreWhite · X

RT @IntegralAnswers: 11B/ Ref: https://t.co/18yBulVJBE

Sep 1, 2025 · 1 share · 2,742 followers View post →
IntegralAnswers
@IntegralAnswers · X

11B/ Ref: https://t.co/18yBulVJBE

Sep 1, 2025 · 5 likes · 1 share · 8,603 followers View post →
吸血鬼
@lvasmira · X

@malditoponyy @TUNKY99 De hecho hay harta evidencia para usarlo en personas sin diabetes, solo com sobrepeso u obesidad. https://t.co/PpLkugzLgY

Dec 26, 2024 · 163 followers View post →
SACardiología
@SACardiologia · X

RT @JTLLERGO: ⚠️ Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A SR and Meta-Analy…

Jun 12, 2024 · 1 share · 5,107 followers View post →
Javier Torres
@JTLLERGO · X

⚠️ Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A SR and Meta-Analysis of RCT‼️

Jun 12, 2024 · 16 likes · 1 share · 5,193 followers View post →
PulsePilot
@Pulse1Pilot · X

RT @drcadesky: If you need more proof that semaglutide (Ozempic, Wegovy) often leads to significant weight loss, here it is 10.1016/j.amjc…

Jun 1, 2024 · 1 share · 5,250 followers View post →
Eric Cadesky MD
@drcadesky · X

If you need more proof that semaglutide (Ozempic, Wegovy) often leads to significant weight loss, here it is 10.1016/j.amjcard.2024.04.041 https://t.co/WYz2AdYTlL

Jun 1, 2024 · 3 likes · 1 share · 4,511 followers View post →
Foolproof Mastery
@FoolproofMaster · X

@DrNadolsky Just saw this cc @TheBhupiThakur https://t.co/6b02L50dkK

May 9, 2024 · 1,175 followers View post →
Satoru Mitsuboshi
@3stars67664378 · X

RT @pinacol: 【システマティックレビュー・メタアナリシス】糖尿病患者体重減少のための週1回セマグルチドの長期間の有効性と安全性（セマグルチドはプラセボと比較して長期間の相対的および絶対的体重減少と関連した。消化管有害事象のリスクはセマグルチドで高かった。） #ペ読…

May 5, 2024 · 1 share · 1,852 followers View post →
pinacol
@pinacol · X

【システマティックレビュー・メタアナリシス】糖尿病患者体重減少のための週1回セマグルチドの長期間の有効性と安全性（セマグルチドはプラセボと比較して長期間の相対的および絶対的体重減少と関連した。消化管有害事象のリスクはセマグルチドで高かった。） #ペ読 https://t.co/sDYotc1IF0

May 5, 2024 · 3 likes · 1 share · 1,683 followers View post →
Tom Mueller
@tommuellerX · X

RT @eric_weinhandl: (1) It works. Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A…

Apr 30, 2024 · 1 share · 3,978 followers View post →
Eric Weinhandl
@eric_weinhandl · X

(1) It works. Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials - American Journal of Cardiology https://t.co/n4SrzRK70E

Apr 29, 2024 · 4 likes · 1 share · 2,801 followers View post →
Zana Antonova
Facebook

The American Journal of Cardiology. 2024 Jul 1:222:121-130. doi: 10.1016/j.amjcard.2024.04.041. John P H Wilding et al. Weight regain and cardiometabolic ...

Dec 23, 2025 View →
Vitalija Kožemiakina (@Vitalyte1) • Facebook
Facebook

The American Journal of Cardiology. 2024 Jul 1:222:121-130. doi: 10.1016/j.amjcard.2024.04.041. John P H Wilding et al. Weight regain and cardiometabolic ...

Dec 23, 2025 View →
Oksana StarVac (@oksana.starvac) • Facebook
Facebook

The American Journal of Cardiology. 2024 Jul 1:222:121-130. doi: 10.1016/j.amjcard.2024.04.041. John P H Wilding et al. Weight regain and cardiometabolic ...

Dec 23, 2025 View →
Sema | PDF | Meta Analysis | Randomized Controlled Trial
News

https://doi.org/10.1016/j.amjcard.2024.04.041 122 The American Journal of Cardiology (www.ajconline.org). publicly preregistered with the Open Science ...

Dec 23, 2025 View →
GLP-1 Receptor Agonists: Trend, Necessity, or Blessing? | AJMC
News

Am J Cardiol. 2024;222:121-130. doi:10.1016/j.amjcard.2024.04.041; Ghusn W, Hurtado MD. Glucagon-like receptor-1 agonists for obesity: weight ...

Dec 19, 2025 View →
Semaglutide and Type 2 Diabetes: Efficacy, Safety, and Outcomes
News

Am J Cardiol 222, 121-130 (2024). https://doi.org/10.1016/j.amjcard.2024.04.041; American College of Cardiology. Semaglutide Effects on ...

Nov 14, 2024 View →
Svarbu
Facebook

The American Journal of Cardiology. 2024 Jul 1:222:121-130. doi: 10.1016/j.amjcard.2024.04.041. John P H Wilding et al. Weight regain and ...

Jul 7, 2024 View →
Apie Adibas dietologijoje/ endokrinologijoje. ⚠️Daugybė ...
Facebook

... Journal of Cardiology. 2024 Jul 1:222:121-130. doi: 10.1016/j.amjcard.2024.04.041. John P H Wilding et al. Weight regain and ...

Jul 7, 2024 View →
Mar 18, 2024 ... The American Journal of Cardiology. 2024 Jul 1:222:121-130. doi: 10.1016/j.amjcard.2024.04.041. John P H Wilding et al. Weight regain and ...
Facebook

The American Journal of Cardiology. 2024 Jul 1:222:121-130. doi: 10.1016/j.amjcard.2024.04.041. John P H Wilding et al. Weight regain and ...

Mar 18, 2024 View →